Beijing Kanova Biopharmaceutical Co., Ltd.

Primary study objective: To evaluate the effect and safety of XKH001 injection on airway hyperresponsiveness after multiple administration in patients with allergic asthma. Secondary study objective: To evaluate the immunogenicity, PK (pharmacokinetic) characteristics and PD (pharmacodynamic) characteristics of XKH001 injection in patients with allergic asthma after multiple administration.

Primary objective: To evaluate the efficacy of XKH004 in the treatment of moderately to severely active AS by the proportion of patients reaching ASAS 40 at 16 weeks of treatment Key secondary objectives: To evaluate the efficacy of XKH004 in the treatment of moderately to severely active AS by the proportion of patients reaching ASAS 20 at 16 weeks of treatment Other secondary objectives: To evaluate the efficacy of XKH004 in the treatment of moderately to severely active AS by other efficacy indicators To evaluate the effect of XKH004 on the improvement of the quality of life of patients with moderately to severely active AS To evaluate the population pharmacokinetic (PPK) characteristics of XKH004 in patients with active AS To further evaluate the safety and immunogenicity of XKH004 in patients with active AS